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ABSTRACT 
 
TALEB SARA, Masters of Science: June : 2018, Biomedical Sciences 
Title: MAGNITUDE OF RSV FUSION PROTEIN-SPECIFIC ANTIBODIES IN 
INFANTS AND CORRESPONDING MOTHERS 
Supervisor of Project: Hadi M. Yassine. 
 
INTRODUCTION: Respiratory syncytial virus (RSV) is a threatening agent causing 
lower respiratory infections (LRI) among children, where no vaccine is available. RSV 
expresses three surface glycoproteins, of which the attachment (G) and fusion (F) are 
targets for neutralizing antibodies (Ab). Being essential for viral entry and highly-
conserved, the F protein is a potential vaccine candidate. To overcome the irreversible 
transition from a metastable Pre-F to a stable Post-F conformation, cavity-filling-
mutations have been designed and introduced to stabilize the F protein structure which 
harbor most of the neutralizing epitopes. This stabilized Pre-F is being considered to 
vaccinate pregnant females and to induce high-level of the maternal Abs that can be 
transferred to infants and protect them during their first critical months of life. Aim: To 
evaluate the level of maternal Abs in RSV-hospitalized children and to investigate their 
correlates to protection ability. METHODS: 65 blood samples and nasal aspirates were 
collected from RSV-infected children at the Pediatric Emergency Center (PEC) at 
Hamad Medical Corporation (HMC) in Qatar, along with blood samples from their 
corresponding mothers. Both maternal and infants’ sera were screened for the presence 
of Pre-F and Post-F Abs using ELISA and neutralization procedures. Further, the 
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circulating RSV subgroups in Qatar were identified by PCR on nasal aspirates, followed 
by sequencing analysis. RESULTS: Children involved in this study raged in age 
between 0 and 6 months (mean: 1.7 ± 1.2). Relatively, low levels of anti-F Abs were 
detected in hospitalized children. Endpoint Ab titers to Pre-F in children ranged 
between 0.03 x 103 and 2.81 x 103 (mean: 0.97 x 103). Anti-F Abs titers in children 
showed positive-correlation with maternal Abs titers, and negative-correlation with 
infants’ age. Only 14% of maternal Abs were detected in infants, with an average of 
0.97 x 103 and 1.12 x 103 Pre-F and Post-F end-point-titers, respectively. Unlike Post-F, 
Pre-F-adsorption diminished almost 80% of binding and neutralizing Ab-titers from 
both maternal and infants’ sera, indicating higher levels of Pre-F Abs. Molecular 
analysis showed interchangeable circulation of RSV subgroups throughout 2016/2017 
and 2017/2018 winter seasons. There was an inverse correlation between infants’ anti-
Pre-F Abs titers and virus titers in nasal swabs. F gene sequence analysis revealed site Ø 
and site II located mutations, some of them were never reported and probably need 
confirmation and others indicated resistance to Palivizumab. CONCLUSION: Our 
results indicate low-levels of maternal Abs in RSV-infected-infants, which partially 
explain children’s susceptibility to the disease. Vaccination of pregnant females in the 
last trimester of pregnancy with Pre-F-protein would guarantee the delivery of high 
levels maternal RSV Pre-F-specific-Ab-titers to neonates and thus protect then against 
RSV-infection during their first critical months of life. 
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I- INTRODUCTION 
 
Respiratory syncytial virus (RSV) is an enveloped non-segmented negative-strand 
RNA virus belonging to the Paramyxoviridae family. It is the most leading cause of 
lower respiratory tract infections (LRTI) in young infants worldwide, with about 33 
million cases and about 160,000 -190,000 deaths annually (Gilman et al., 2016; Ngwuta 
et al., 2015; Sastry et al., 2017). According to a recent study, 6.7% of all deaths in less 
than 1 year infants is due to RSV infection (Nair et al., 2010). RSV hospitalization is 
common throughout the first 5 years of age, however, it peaks among 2-3 months old 
infants (Graham, 2017).  By the age of 2-3 years, most of the children get infected with 
this virus (Widjaja et al., 2016), then reinfected repeatedly for lifetime as the host 
immunity to RSV diminishes over time (Varga & Braciale, 2013). Infection with RSV 
is manifested by airway obstruction, runny nose, shortness of breath, wheezing, 
hypoxia, and in severe cases, pneumonia and bronchiolitis (Graham, 2017). Adding to 
that, development of asthma has been highly associated to RSV (Sawadkohi et al., 
2012). 
RSV genome contains more than 15,000 nucleotides coding for at least 11 
proteins (Collins, 1991; Collins et al., 1986; Graham, Modjarrad, & McLellan, 2015). 
(G), (F) and (SH) are surface proteins (Kingsbury, 2012). As the name signifies, 
attachment protein (G) helps attaching the virus to host cells, and Fusion protein (F) is 
responsible for viral fusion and syncytium formation. Small Hydrophobic (SH) protein, 
not-well understood, seems to improves virus entry to the host cell (Tripp, Jorquera, & 
Tripp, 2016), while the Matrix (M) protein serves as the inner envelope protein 
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(Kingsbury, 2012). Four nucleocapsid-associated proteins symbolize viral replication 
machinery: Nucleoprotein (N), Phosphoprotein (P), Large (L) and (M2-1) proteins (Li 
et al., 2014; Nair et al., 2010). M2-2 protein, encoded by downstream open reading 
frame of M2, is responsible for RNA synthesis during virion assembly (Collins, 1991). 
NS1 and NS2 are non-structural proteins and are suspected to play a role in IFN release 
inhibition from infected cells (Barik, 2013) (Chin et al.) [Figure 1]. 
RSV strains are classified into 2 main subgroups: RSV-A and RSV-B. Despite 
sharing comparable infectivity and epidemiology profile, both subgroups are 
antigenically distinct with about 47-50% genetic differences in the G glycoprotein and 
8-10% differences in the F glycoprotein (Chamat et al., 1999; Fuentes, Coyle, Beeler, 
Golding, & Khurana, 2016; Mufson, Örvell, Rafnar, & Norrby, 1985). Like other 
respiratory viruses, RSV infections tend to increase in cold weather, low temperature 
and following rainfall. In temperate climate countries, RSV circulates throughout winter 
season, but peaks during December or January (Aamir, Alam, Sadia, Zaidi, & Kazi, 
2013). In tropical countries, RSV causes outbreaks in hot, humid, rainy days during 
June to November period (Al-Toum, Bdour, & Ayyash). 
For RSV treatment, Ribavirin is given to severely infected patients. Further 
Palivizumab, the only FDA approved monoclonal antibody, is recommended by the 
American Academy of Pediatrics (AAP) for infants at high risk (e.g. immune-
compromised, premature, congenital heart- or chronic lung-diseased) (Diseases, 2009; 
Simoes, 1999; Turner et al., 2014). These treatments are limited in use among adults. 
Hence, vaccination would be the optimal method to protect immune-compromised 
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adults from RSV illness and complications. Still, no vaccine has been licensed, 
specifically after the failure of Formalin-inactivated RSV vaccine which resulted in 
enhanced disease illness in the vaccinated group (Modjarrad, Giersing, Kaslow, Smith, 
& Moorthy, 2016; Simões et al., 2015). 
G glycoprotein, a target for neutralizing Abs, is antigenically variable making it 
challenging to create a broadly protective vaccine. On the other hand, the F 
glycoprotein, which is another target for neutralizing Abs, is highly conserved among 
circulating strains. Nonetheless, F-protein is presented on the virion surface in two 
forms: one metastable structure, called pre-fusion (Pre-F), which is disposed to switch 
unpredictably to another stable post-fusion (Post-F) structure (Mousa, Kose, Matta, 
Gilchuk, & Crowe Jr, 2017). Despite the fact that G and F glycoproteins provoke 
neutralizing Abs elicitation, F is the major vaccine development target since it is 
essential for viral entry, is more conserved, and presents more epitopes targeted by 
neutralizing Abs (Beeler & van Wyke Coelingh, 1989; Magro et al., 2012; Ngwuta et 
al., 2015). To date, six antigenic sites for neutralization have been identified on Pre-F 
and Post-F conformations. Site I, a weak neutralizing epitope discovered by an escape 
mutation (P389), binds to 2F and 44F monoclonal Abs (Calder et al., 2000; Ngwuta et 
al., 2015). Site II binds to Palivizumab, the only FDA approved prophylactic 
monoclonal antibody provided for RSV-infected infants at high risk (Rogovik, Carleton, 
Solimano, & Goldman, 2010). Site IV, a moderate neutralizing epitope, binds to 101F 
and 19 monoclonal Abs (Magro, Andreu, Gómez-Puertas, Melero, & Palomo, 2010; G 
Taylor, Stott, Furze, Ford, & Sopp, 1992). Site V, is a quaternary epitope found on the 
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Pre-F only and it binds to AM14 monoclonal antibody (Killikelly, Kanekiyo, & 
Graham, 2016; McLellan et al., 2010). Most importantly, site Ø, another Pre-F specific 
epitope, binds to D25, 5C4 and AM22 monoclonal Abs which have 100-times more 
neutralizing activity than Palivizumab (McLellan, Chen, Leung, et al., 2013). Other Pre-
F specific monoclonal Abs were discovered such as MPE8 which binds near site II 
(Corti et al., 2013; Gilman et al., 2015; Ngwuta et al., 2015). Because of Pre-F 
structure’s high potency in neutralization, researchers have recently established a 
stabilized Pre-F form by protein engineering to be used as putative RSV vaccine 
(Gilman et al., 2016; Krarup et al., 2015; McLellan, Chen, Leung, et al., 2013) [Figure 
2]. 
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Figure 1: RSV proteins (a) and genetic makeup (b). (a) Location of 11 RSV proteins at 
an electron microscope image of the virus [V: virion and F: filamentous cytoplasm], and 
their corresponding functions. (b) Map of the negative sense RNA genome (RSV strain 
A2) where (nt) and (aa) indicate nucleotides and amino acid lengths, respectively. (le) 
and (tr) represent leader and trailer, respectively. Intergenic regions are underlined, and 
the length of the gene overlap is in parentheses. Adopted from (Collins & Melero, 2011). 
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Figure 2: Location of six antigenic sites on Prefusion (Left) and Postfusion (right) 
structures of RSV F glycoprotein and their neutralizing potency.  
Adopted from (Graham, 2017). 
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AIM:  
Considering the failures in the previous vaccine trials, an alternative strategy to protect 
young infants from RSV infection could be through maternal Abs transfer. Accordingly, 
one potential strategy that is being considered is to vaccinate pregnant women in their 
last trimester with stabilized Pre-F protein to boost their immune responses to RSV. 
This will ensure the delivery of high RSV-Abs titers to their babies, which will protect 
them from infection during the first critical months of life. However, the role of Pre-F 
maternal Abs in few months old infants has not been investigated so far. Therefore, this 
project aims to determine the magnitude of maternally-derived RSV-Abs against Pre-F 
and Post-F conformations in infants in comparison of their mothers, and consequently 
define the outcome of introducing a stabilized Pre-F prospective vaccination to pregnant 
woman. 
 
OBJECTIVES: 
1. Measuring binding Pre-F specific Abs in sera from infants and pediatrics 
admitted to PEC with RSV infection.  
2. Measuring binding Post-F specific Abs in sera from infants and pediatrics 
admitted to PEC with RSV infection.  
3. Measuring binding Pre-F specific Abs in sera from mothers correspondent to 
infants and pediatrics admitted to PEC with RSV infection.  
4. Measuring binding Post-F specific Abs in sera from mothers correspondent to 
infants and pediatrics admitted to PEC with RSV infection.  
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5. Determine the correlation between infants’ Abs against Pre-F and Post-F 
proteins and demographics, disease severity and viral load/subgroups. 
6. Determine the correlation between magnitude of maternal Abs against Pre-F and 
Post-F proteins in hospitalized infants and manifestation of the disease. 
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II- LITERATURE REVIEW 
 
 
2.1 RSV molecular biology 
RSV genome is a negative sense ssRNA containing more than 15000 nucleotides 
and encodes for 11 proteins. F, G and SH are the only glycoproteins expressed on the 
surface of the virion (Kingsbury, 2012). 
F protein is a class I fusion protein composed of 574 amino acid (aa). With a 
molecular weight of a 50 kDa and two subdomains, C-terminal fragment F1 and a 20 
kDa N-terminal fragment F2, the protein acquires a trimer of heterodimers (Graham et 
al., 2015). At amino acid positions 109 and 136, two furin cleavages take place. This 
feature releases a glycopeptide and thus reveals the hydrophobic site at F1 fragment. F1 
and F2 are linked by a cysteine-rich region at two positions: between aa70 and aa212, 
and between aa37 and aa439. Other F-related features involve N-glycosylation in F1 at 
aa position 500, and in F2 at aa positions 27 and 70. F protein is highly conserved, with 
only 25 aa differences between RSV subgroup A and B (Graham et al., 2015). 
G protein is a type II integral membrane protein composed of 298aa with a 
molecular weight of 90kDa. It is highly glycosylated and is expressed in two forms, 
secreted and membrane-anchored, called Gs and Gm, respectively. Gs is linked to 
neutralization inhibition, while Gm is related to viral attachment. This virus-host- 
membrane attachment is mediated by heparin sulfate proteoglycans receptor interaction. 
The antigenic variation is located in the mucin domain of G protein at both C- and N-
terminal ends. N- and O-glycosylation enables the protein to mature and enhances 
immune escape mechanisms. Other feature includes a central conserved region (CX3C 
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motif) which is responsible for CX3CR1 binding to diminish inflammatory cytokines 
release (Graham et al., 2015; Kingsbury, 2012; Tripp et al., 2016; Wertz et al., 1985).  
 
2.2 RSV pathogenesis 
Studies regarding pulmonary immune cells in young infants are difficult to 
implement due to ethical and technical obstacles. Instead, different animal models have 
been used to study RSV pathogenesis and immune responses to RSV infection 
(Openshaw, 2013).  Further, most researches study immune responses to RSV infection 
in adults more than neonatal models. For that reason, RSV pathogenesis in infants 
remains incompletely understood (Ruckwardt, Morabito, & Graham, 2016). 
RSV is the most common agent for LRTI among children below the age of five. 
Most of those acquire mild to moderate disease manifestations, and 2-3% progress to 
severe illness resulting in hospitalization (Graham, 2017). Factors contributing in RSV 
pathogenesis and disease severity could be environmental, viral and host factors 
(Watkiss, 2012). 
2.2.1 Environmental factors:  
Exposure to smoke, beside its negative effect in general, has been reported to increase 
the risk of RSV infection, bronchiolitis and disease severity (Bradley et al., 2005; Karr 
et al., 2009). Cigarette smoking directly effects primary airway epithelial cells, resulting 
in necrosis which induces inflammation and enhances viral load (Groskreutz et al., 
2009). Cold weather is another favorable factor for RSV spread and infection. It has 
been found that this virus circulates more in cold months, where the virus is highly 
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sensitive to high temperatures and get inactivated within few hours on furniture and 
surfaces at room temperature (Hambling, 1964). 
2.2.2 Viral factors:   
RSV has various mechanisms to enhance its replication and pathogenesis. The main cell 
targets of this virus are type I alveolar cells and superficial airway epithelial cells (J. E. 
Johnson, Gonzales, Olson, Wright, & Graham, 2007). RSV infection results in 
disruption of ciliated epithelial cells, followed by mononuclear cell infiltration, mucosal 
edema, and syncytia formation (Wright et al., 2005). One of the important alternation 
that the virus cause inside the host cell is in cell-cycle-regulatory proteins, resulting in 
accumulation of G0/G1 cell population and thus enhanced viral replication (Wu et al., 
2011). Infectivity, disease severity and increased cytopathology are directly linked to 
viral load as well as to the strain/isolate specificity (DeVincenzo et al., 2010). For 
instance, studies revealed that infection with subgroup A-strain 19 causes elevated IL-
13 excretion, airway hypersensitivity and mucus production in mice (Moore et al., 
2009). A2001/2-20 isolate, on the other hand, initiates more severe complications than 
strain A2, strain 19, Long, and A2001/3-12, including epithelial desquamation and 
bronchiolitis (Stokes et al., 2011). Further, RSV disguises and manipulates the host 
immunity through different mechanisms. For example, NS1 and NS2 proteins are 
known to block the release of type I IFN (IFNa and IFNb) from infected epithelial cells 
via JAK/STAT pathway or toll-like receptor (TLR), resulting in interrupted dendritic 
cells recruitment and the subsequent adaptive immune response cascade (Barik, 2013). 
Further, NS1 and NS2 proteins downgrade cell apoptosis through PI3k pathway 
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activation to prolongate infected cells survival for more viral replication (Bitko et al., 
2007). G glycoprotein is another source of immune escape. It is able to limit the 
function of CX3CL1-mediated CXCR1 leukocytes recruitment (NK, CD4+ and CD8+ 
T cells) (Tripp et al., 2001), decoy neutralizing Abs and delay antigen recognition 
because of its high genetic variation and glycosylation. Gs, a secreted form of G 
glycoprotein, plays the role of binding to RSV Abs and diminishing neutralization of 
the virus (Bukreyev et al., 2008). Moreover, this short form acts as a TLR antagonist to 
downregulate early inflammatory responses released from infected cells through TLR-2, 
-4, -9 (Polack et al., 2005) (Lukacs, Smit, Schaller, & Lindell, 2008). 
2.2.3 Host factors:  
RSV-induced LRTI severity is influenced by several host factors. Any damage or 
incomplete development of to the respiratory tract enhances the pathogenesis of the 
virus. Reports showed an association of vitamin D deficiency in early life to LRTI 
severity (Belderbos et al., 2011). In general, RSV infection is more prevalent at age 
extremity, among premature babies, males, those who have congenital heart disease or 
chronic lung disease or immunodeficiency, and in case of low birth weight and low 
maternal Abs titer (Watkiss, 2012). Host genetic variation plays a key part in any 
infection severity and response, including RSV. The reported genetic polymorphisms 
involve: innate and adaptive defense genes, surfactant protein genes, host cell receptor 
genes, Th1/Th2 response genes (Watkiss, 2012). Imbalances or defects in cytokines 
release from infected cells, macrophages or dendritic cells, influence down-stream 
activation of adaptive immunity. Knowing the importance of cellular adaptive 
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components in viral clearance, proper T cell activation and differentiation guarantees 
controlled RSV spread and infectivity. For that, Th1 to Th2 imbalance or Th2-biased 
immunity could result in an enhanced respiratory diseases as seen in the previous 
vaccination trails using FI-RSV (Littel‐van den Hurk, Mapletoft, Arsic, & Kovacs‐
Nolan, 2007) [Figure 3]. 
 
 
 
 
Figure 3: Environmental, viral, and host factors involved in RSV pathogenesis. 
Adopted from (Watkiss, 2012).  
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2.3 Immunity to RSV 
2.3.1 Innate immune system responses 
Early life immunity can be described as suppressive. Due to organs/systems 
development and the presence of circulating maternal immunoglobulins in few months-
old babies, the immune system is designed to be tolerant and defective in quality and 
quantity (Gervassi & Horton, 2014; Ruckwardt et al., 2016). For example, fetal CD4+ T 
cells were revealed to differentiate into more T regulatory (Treg) cells as a mechanism 
of immune tolerance towards maternal Abs and developing organs, rendering the 
immunity adaptive to early life needs rather than defective (Mold et al., 2010). 
Nevertheless, these features make young infants more susceptible to infections 
compared to older children and adults. Among suppressed immune components, natural 
killer (NK) cells were found to be modulated through transforming growth factors beta 
(TGFβ) secreted by Treg (Ndure & Flanagan, 2014). Neutrophils as well were found to 
have reduced cytokines release and phagocytic function (Dowling & Levy, 2014). 
Dendritic cells (DC) and subtypes, essential parties to link innate to adaptive immunity, 
were found limited in number and function such as recognizing, processing, and 
presenting foreign antigens to T cells. These deficiencies tend to stimulate the immune 
system towards Th2 differentiation (Cormier et al., 2014; Marr et al., 2014; Ruckwardt, 
Malloy, Morabito, & Graham, 2014). Up to the present time, immunomodulation 
remains an incompletely discovered process, and further investigation is required to 
understand early life immunity, hoping to find the appropriate methods for young 
infants’ protection from RSV infections, for instance.  
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Activation of adaptive immunity depends on efficiency of innate immunity. Antigen 
presentation is the critical point to induce adaptive defenses and thus the following up 
functions. Viral clearance and protective antibody production are the expected results 
from T cell and B cell contributions. However, the early life alternations in innate 
defense influence critically the whole process from adaptive immunity activation to 
antibody production and viral clearance (Malloy, Falsey, & Ruckwardt, 2013). 
 
2.3.2 Adaptive immune system responses 
As mentioned above, DC trigger T cells to activate and differentiate into T cytotoxic. 
This role is disturbed by every limitation occurring in DC at early life resulting in 
disturbance/imbalance of immune system efficacy (Iwasaki & Medzhitov, 2015). CD4+ 
T cells were found to lose the balance to differentiate toward Th1 and Th2 in response 
to infectious diseases at early stage of life, confirming that immunomodulation resulted 
in Th2-derived immune response (L. Lambert, A. M. Sagfors, P. J. Openshaw, & F. J. 
Culley, 2014a).  Previous studies have confirmed the association of enhanced disease 
illness resulting of formalin-inactivated RSV (FI-RSV) to Th2-driven pathology 
(Karron, Buchholz, & Collins, 2013). CD8+ T cells play an essential role in protection 
from viral infections (J. Liu et al., 2016). They participate in all situations of viral 
clearance once the infection is striking (Morabito et al., 2017). Cases of RSV infections 
with decreased CD8+ levels such as in severe combined immune-deficiency (SCID), 
bone marrow (BM) or lung transplantation have led to death (Ruckwardt et al., 2016). 
At early life, CD8+ T cells are also lacking, resulting in severe RSV infection that could 
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be fatal (Welliver et al., 2007). Another limitation at early life which have been 
documented is antibody production. The importance of Abs manifests in some Fc-
accelerated auxiliary processes of viral clearance, and young children’s protection from 
severe RSV illness, particularly neutralizing Abs which reduce the number of infected 
cells and delay the virus from reaching to lower respiratory tract (Groothuis, Simoes, 
Hemming, & Group, 1995). Therefore, decreased antibody production and responses 
may contribute in RSV severity. This antibody inadequacy raises from B cells shortage 
and inability to promote somatic mutation (Basha, Surendran, & Pichichero, 2014). 
According to one study, RSV neutralizing immunoglobulins are unlikely to develop 
after a natural RSV infection during the first four months of life. That is, B cells start to 
increase and mature gradually at 4-6 months old, resulting in significant increase of 
neutralizing Abs after 6 months of age (Sande, Cane, & Nokes, 2014). These findings 
confirm the ineffectiveness of vaccination prior four months of age since both innate 
and adaptive immune system are suppressive, and instead empower the need of 
alternative source of protection to compensate neonatal immunity. [Figure 4] 
2.3.3 RSV Mechanisms of immune escape  
The ability of RSV reinfections in individuals throughout life is attributed partially to 
the weakening of host immunity to this pathogen over time. Further, the virus evolved 
various mechanisms to avoid immune system despite its limited genetic variation. Three 
main classes of immune escape are exerted by the virus: 1.  location-related infectivity, 
2. conformational avoidance from neutralization/neutralizing antibody, and 3. functional 
change of the immunity. Infecting the ciliated epithelial cells (superficial) of the 
16 
 
  
   
respiratory airways saves the virus from getting exposed to dendritic cells, responsible 
for transporting RSV antigen to lymph node to recruit immune reactions (J. E. Johnson 
et al., 2007; Zhang, Peeples, Boucher, Collins, & Pickles, 2002). To avoid neutralizing 
Abs, the structure of F protein, responsible for virus-host and cell-cell fusion, changes 
conformation from a metastable to stable form so called Pre-F and Post-F, respectively. 
Since Pre-F is the required part for viral fusion and the target for more potent 
neutralizing Abs, RSV balances between both functions by transitioning to Post-F in a 
smartly calculated manner to enter the cell (remain infectious) and escape neutralization 
by Pre-F-specific Abs (Hambling, 1964; Killikelly et al., 2016). Lastly, modulating host 
immunity initiates when RSV targets young infants. Because they have naive immune 
system (immature dendritic cells, deficiency of B cell somatic hyper-mutation) 
(Lambert et al., 2014a), the virus inhibits type I IFN through NS1 and NS2 proteins 
(Barik, 2013), manipulates dendritic cell signaling through G glycoprotein (T. R. 
Johnson, McLellan, & Graham, 2012), and tricks antibody neutralizing responses 
through secreted form of G glycoprotein  (Bukreyev et al., 2008).  
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Figure 4. Early life immunity responses towards RSV infection. Neonatal innate 
response following RSV infection is weak: low levels of cytokines, such as interferons, 
diminished TLRs signals, altered antigen presenting function, and reduced activation of 
regulatory T cells. This results in a skewed adaptive response toward Th2 and low CTL 
activation through Th1. Impaired Tfh activation, little or no B cell memory and 
inhibition of antibody production by IFNγ, results in low titer and low affinity Abs. 
Consequences of suppressive immune response lead to bronchiolitis in susceptible 
infants. Adopted from (L. Lambert, A. M. Sagfors, P. J. M. Openshaw, & F. J. Culley, 
2014b)  
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2.4 RSV vaccine history and enhanced respiratory illness 
Although RSV disease is believed to be an ancient agent, the virus was first 
identified in 1955 as “Chimpanzee Coryza Agent”, then a year later was linked with 
bronchiolitis in young children (Morris, Blount Jr, & Savage, 1956). Few years later, a 
vaccine attempt was done using formalin-inactivated RSV given to young children. The 
idea of producing a formalin-inactivated RSV vaccine was inspired from previous 
successful trials such as in Polio (KIM et al., 1969). In four separate studies, the FI-RSV 
vaccine was given at a 3-dose regimen (0, 1, 4 months) for 2-7 months old infants 
(Killikelly et al., 2016). Unfortunately, the experiment failed and resulted in enhanced 
respiratory diseases following a natural RSV infection, in which 16/20 (80%) of the 
vaccinated children were hospitalized, compared to 5% of non-vaccinated children, and 
2/20 (10%) passed away (KIM et al., 1969). Enhanced respiratory disease in FI-RSV 
was characterized by development of antibodies directed more towards Post-F non-
neutralizing epitopes. Those antibodies, following a natural RSV infection, induced 
Th2-derived immune responses (Connors et al., 1992) (Connors et al., 1994). Induced 
binding-Abs were found to have a low neutralizing activity (Murphy & Walsh, 1988), 
and were associated with immune complex deposition and complement activation in 
airways (Killikelly et al., 2016; Ruckwardt et al., 2016). Eosinophilia was another 
characteristic of FI-RSV, causing hypersensitive peri-bronchiolar inflammation 
regulated by IL-4, IL-5, IL-13 and IgE (Knudson, Hartwig, Meyerholz, & Varga, 2015), 
in addition to low CD8+ T cells activation, following RSV infection in FI-RSV 
vaccinated individuals (Polack, 2015). These immunological features (humoral and 
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cellular) involved in FI-RSV enhanced diseases explain the reason behind this vaccine 
failure.  
According to recent studies, Pre-F conformation provoke stronger neutralizing 
Abs as compared to Post-F. Yet, based on one study, the expression of Pre-F antigens 
on the surface of the virus was almost lost within the 72 hours of formalin fixation 
period (Killikelly et al., 2016). Therefore, to develop an efficient vaccine without 
complications such as enhanced illnesses, it is critical to consider the consequences of 
viral inactivation and formalin concentration (McLellan, Chen, Joyce, et al., 2013; 
Moghaddam et al., 2006). Viral inactivation alters antigenicity and immunogenicity. 
Formalin, a chemical fixative/preservative to inactivate viruses, creates different 
outcomes using different concentrations where high concentration of 1% destroys viral 
infectivity via inter- and intra-protein cross-linkage, and while lower concentrations 
preserve antigenic epitopes differently (Clemens et al., 1995; Furesz, Scheifele, & 
Palkonyay, 1995). 
Following FI-RSV vaccine experimentation, other trials of live-attenuated virus 
vaccine were established. Side-effects were also observed with such vaccines and 
therefore were not approved for infants because of their failure to preserve antigenicity 
and immunogenicity (Karron et al., 2013; Ruckwardt et al., 2016). 
 
2.5 F protein-based neutralization 
Structures of Pre-F, Post-F proteins and their corresponding epitopes are depicted 
in figure 2. Several recent studies have demonstrated the relationship between Pre-F and 
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Post-F binding Abs and their neutralizing activities. Structural and immunological 
analysis demonstrated that Pre-F-specific Abs are at least 8-fold more potent than 
shared (Pre-F and Post-F cross-reactive) Abs and 80-fold more potent than Post-F-
specific Abs (Gilman et al., 2016; McLellan, Chen, Joyce, et al., 2013). Adsorption of 
sera of individuals aged between 7 to 93 years with stabilized Pre-F protein removed 
>90% of neutralizing activity, and diminished binding Abs to both F conformations. On 
the other hand, sera adsorbed with Post-F retained most of the neutralizing activity 
(>70%) as well as the binding Abs to Pre-F conformation (Ngwuta et al., 2015). These 
findings demonstrate a positive correlation between Pre-F binding and virus 
neutralization (Zhao M. et al. (2017)), while the correspondence of Post-F binding and 
neutralization was not significant (Graham et al., 2015). The study further investigated 
neutralization activity at the epitope level to compare well-identified antigenic sites 
present on Pre-F and Post-F conformations. 60% of highly potent neutralizing Abs were 
targeted to site Ø and V, which are Pre-F specific antigens. Meanwhile, site III and IV, 
shared between Pre-F and Post-F, represented targets for moderate neutralizing Abs, 
followed by Site I and II, which represented targets for weak neutralizing Abs (Widjaja 
et al., 2016). These differences in neutralization towards both F conformations could 
possibly be explained by the uniqueness, the accessibility and the approach angle of 
each antigenic site (Gilman et al., 2016).  
2.5.1 Palivizumab and recently discovered RSV antibodies 
Palivizumab is the only licensed humanized monoclonal antibody and is designed to 
identify a shared antigenic epitope between Pre-F and Post-F, site II, in the hope of 
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increasing its target spectrum. Determination of Pre-F structure in complex with D25 
antibody (McLellan, Chen, Leung, et al., 2013) and subsequent stabilization of the 
protein with cavity-filling hydrophobic substitution mutations (McLellan, Chen, Joyce, 
et al., 2013), enabled better understanding of the immune response to the two forms of 
this metastable protein.  It was found that Pre-F preserve more antigenic sites compared 
to Post-F, which are the target for more potent neutralizing Abs than Palivizumab’s 
antigenic site. Various studies have compared the neutralizing potency of site II to 
particularly Pre-F-specific epitopes. Palivizumab or 1129 antibody showed comparable 
binding affinity to its appropriate antigenic site on both forms of the protein. However, 
site Ø-specific antibody 5C4 expressed 50-fold more neutralizing activity than 1129 in 
mice, and decreased RSV titers by 1000-fold more than Palivizumab, suggesting that 
site Ø elicits more protective Abs from RSV infection than site II (Zhao et al., 2017). 
Site V, another Pre-F-specific site, was also investigated against Palivizumab-site II. 
AM14, a quaternary Pre-F-specific antibody, neutralized all tested RSV strains, with 
IC50s of: 13.6 ng/ml for strain A Long, 12.4 ng/ml for strain A2, 30.8 ng/ml for 
subgroup B strain 18537 and 4.6 ng/ml for subgroup B strain 9320, compared to 
Palivizumab which neutralized the same strains with IC50s of 300 ng/ml, 320 ng/ml, 
380 ng/ml and 120 ng/ml, respectively. These data suggested that Abs to site V are 100-
fold more potent than site II directed Abs (Gilman et al., 2015).  Recently, a new Pre-F 
specific epitope was discovered and is referred to as site VIII. This site was shown to 
reside between site II and site Ø. mAb 90, specific to this new site, neutralized 3 tested 
RSV strains of A2, 18537 B, and Long with IC50s of 4 ng/ml, 10 ng/ml, and 35 ng/ml, 
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respectively, compared to Palivizumab IC50s of 1900 ng/ml, 1300 ng/ml, and 212 
ng/ml, of the same RSV strains. These findings as well confirm 1000-fold more potency 
of site VIII than site II (Mousa et al., 2017). The main conclusion from this comparison 
is to emphasize the important role of Pre-F-specific Abs in RSV infection prevention, 
and the potential use of Pre-F antigen as an effective vaccine. Particularly that 
Palivizumab is at high cost, given only to high-risk premature infants, restricted for 
adults with immunodeficiency or elderly people, and has low in neutralizing activity.  
 
2.6 RSV vaccine approaches 
The reverse outcomes of FI-RSV vaccine and virus-attenuated trials invigorated 
researchers to develop and test new vaccine concepts that avoids side effects and 
complications. The nature RSV infectivity, the host immune responses at early life 
including the impact of imbalanced Th1 to Th2 immunopathology, and the viral 
mechanisms to escape immunity are all decisive points towards developing RSV 
vaccine. Since infection with RSV is more dramatic in infants less than three months of 
age, and implementing an efficient primary vaccination at this stage is challenging, 
alternative sources of protection shall be considered to support their immune system 
during this critical period. Passive immunity towards RSV can reduce RSV burden, if 
enough protective maternal Abs titers are delivered to the neonates (Lambert et al., 
2014b). Further, the use of Palivizumab for therapy indicate the importance of 
neutralizing Abs in protection from severe RSV infection.  Characterizing the stabilized 
Pre-F protein as a main target for neutralizing Abs, particularly those to site Ø which 
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are 100-1000fold more potent than the licensed monoclonal antibody, has opened the 
door towards using it as a putative vaccine  (Graham, 2017; Mousa et al., 2017; Ngwuta 
et al., 2015; Zhao et al., 2017). On the other hand, the selection of appropriate adjuvant 
influences immunogenicity or/and immunogenicity. One recent study assessed the 
impact of different adjuvants on vaccine efficiency and immune responses. It was found 
that an oil-in-water adjuvant, Sigma adjuvant system (SAS) plus Carbopol, induced the 
highest RSV neutralizing antibody responses, followed by Alum, SAS alone, AdjuPlex, 
and Poly (I:C). TLR4 agonist MPLA, Alum plus MPLA or AddaVax generated 
moderate responses. All these findings were compared to DS-Cav1 (stabilized Pre-F 
protein) alone without adjuvant which induced much lower response. When elderly 
mice with pre-existing immunity against DS-Cav1 were tested for an immune boost 
with DC-Cav1 plus an adjuvant, results showed that SAS plus Carbopol enhanced 
immune responses 2- to 3-fold, while Alum enhanced immunity by 5-fold (Sastry et al., 
2017).  
One of the main strategies is to vaccinate pregnant women prior delivery to boost 
their pre-existing Pre-F-specific Abs (Graham, 2017). Transferred maternal Abs would 
protect young infants for up to 6 months, enough for the early immunity to maturate and 
develop naturally anti-RSV Abs following upcoming RSV infections (Lambert et al., 
2014b). This potential vaccine could also be administrated to children once their 
immune system is stable and adequate. As a delivery method, other strategies described 
the use of vectors (Geraldine Taylor et al., 2015) and nucleic acids (Pardi & Weissman, 
2017). A study has recently claimed a preclinical development of RSV F vaccine by 
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expressing a stabilized Pre-F via human parainfluenza type 1 (HPIV1) recombinant 
vector. RSV F was expressed as a full-length protein or as a chimeric form with HPIV1 
F transmembrane and cytoplasmic tail (TMCT) domains. Results showed that full-
length was more immunogenic in terms of neutralization and protection following RSV 
challenge, compared to the chimeric form with TMCT modification which had reduced 
immunogenicity (Liu et al., 2017). Another study used human parainfluenza type 3 as a 
vector to deliver the vaccine and codon-optimized Pre-F gene was incorporated. 
Optimized-codon with low CpG enabled the virus to better express Pre-F protein, 
reduce IFN release and replicate efficaciously in vivo. This bivalent RSV/HPIV3 
vaccine (DS-Cav1 Pre-F stabilization, reduced CpG content, and vector packaging 
combination) improved F immunogenicity, induced higher complement-independent 
Abs titers and resulted in better protection following RSV challenge in hamsters (Liang 
et al., 2017). 
All these approaches aim to develop the most appropriate RSV vaccine candidate, 
preserving Pre-F expression for an enhanced immunogenicity and protective immune 
responses. Antigen-naïve population is the main target for these vaccine trials, yet, older 
children, immunocompromised adults and elderly people are potential candidates for 
RSV vaccination. 
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III- METHODS AND MATERIALS 
 
3.1 Study design:  
Stabilization of the Pre-F protein has opened new doors to understand the pathogenicity 
and immune response to RSV infection. Considering the propose of Pre-F vaccine trials 
in pregnant women, we sought to determine the correlation between the F-specific 
maternal Ab responses to RSV in infants  and manifestation of the disease. This cohort 
study was initially designed to enroll 100-200 patients admitted with RSV infection to 
Pediatric Emergency Center (PEC) of Hamad Medical Corporation (HMC). Ethical 
approvals to collect blood samples (from infants and their mothers) and nasal 
swabs/nasopharyngeal aspirations (from RSV-infected infants only)  were obtained from 
HMC (HMC-IRB 16196/16) and QU (QU-IRB 890-E/18). Because of the nature of 
RSV seasonality, we were able to collect samples from only 65 RSV-positive children 
and their corresponding mothers. Enrollment criteria consisted of the following: 1. 
Infected infants should be hospitalized at PEC, 2. Infants should be RSV-positive only 
(tested at PEC), 3. RSV-infection should be a primary infection, 4. Infants’ age should 
be maximum 6 months old, 5. Samples from enrolled infants should be collected before 
receiving any treatment. Once RSV-infection was confirmed by PEC through PCR, all 
corresponding guardians/mothers signed consent forms before the collection of samples. 
Blood and nasal aspirate samples were transported to Biomedical Research Center 
(BRC) – Qatar University (QU) for further analysis. Blood samples were used to 
separate sera and measure RSV-F binding and neutralizing Abs titers in infants and 
corresponding mothers. Further, nasal swabs/aspirations were used to determine RSV 
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subgroups, Fusion (F) glycoprotein sequences, and viral load. All 65 infants were 0-6 
months old, previously healthy, and hospitalized with RSV primary infection. Clinical 
data, like presenting signs and symptoms, length of stay, birth history, and bronchiolitis 
score at admission and discharge were extracted from patients’ file by PEC research 
team. Molecular and comparative analysis were done to find correlation between 
obtained finding and disease manifestation in RSV-infected infants. 
 
3.2 Viruses and cells:  
Virus stocks (kindly provided by Viral Pathogenesis Laboratory, Vaccine Research 
Center, National Institute of Health, USA) were propagated in HEp-2 cells 
(ATCC® CCL-23™) cultured in 10% minimum  essential medium (MEM). As described 
in (Ngwuta et al., 2015), at 80% confluency in T75 flask, cells were infected with 1 ml 
of RSV A2 and incubated for 1-hour at 37oC. 2-3 ml of 10%  MEM were then added, 
then infected cells were incubated at 37°C for 4 days. When substantial syncytia had 
formed, cells were scraped loose from the  flask, transferred to 50 ml tubes for 
sonication (50% amp. six 1s bursts) and centrifuged at 4°C and  1300 rpm for 15 min. 
These were added to the original supernatant containing virus,  aliquoted into dram 
vials, and stored at −80°C (Graham, Perkins, Wright, & Karzon, 1988). 
3.2.1 Virus quantification by plaque assay: 
Serial dilutions of generated virus stock were prepared from 1:101 to 1:107 in complete 
media (10% MEM). At 80% confluency of HEp-2 cells, seeded a day before at a 
concentration of 2.5 x 105 in 1 ml of 10% MEM per well using 12-well plate, 50 µl of 
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the virus at different dilutions were added to each well in triplicate. After 1-hour 
incubation, rocking, at 37oC, 1 ml of methyl cellulose (autoclaved 3.75g of methyl 
cellulose in 500 ml of complete media) was added to cover each well, then incubated at 
37°C for 4-5 days. 1 ml of 10% formalin was added to each well to fix the cells, then 
incubated at RT for at least 1-hour. All wells were washed with water, stained with 150 
µl of crystal violet for 20 minutes, then washed again with water. Plaques were counted 
after an overnight air dry in triplicate and plaque forming units per ml (PFU/ml) were 
determined using the following formula: average of plaques in one dilution / (dilution 
factor x volume of inoculum in ml [0.05 ml]). 
 
3.3 Proteins production and purification:  
Pre-F (DS-Cav1) and Post-F RSV proteins and vectors for protein expression were 
kindly  provided by Viral Pathogenesis Laboratory, Vaccine Research Center, National 
Institute of  Health. Further protein expression was done as previously described 
(Ngwuta et al., 2015). Plasmids were amplified in Escherichia coli competent cells and 
purified using PureLink™ HiPure Plasmid Maxiprep Kit (Cat # K210006, Invitrogen, 
USA). Plasmids were transfected into Expi293F cells using 293Fectin™ Transfection 
reagent (Cat # 12347019, Invitrogen, USA). The culture supernatants were harvested 5 
days after transfection and centrifuged at 10,000 rpm to remove cell debris. 
Supernatants were then sterile-filtered, and RSV F glycoproteins were first purified by 
affinity columns using Ni2+–nitrilotriacetic acid (Cat # K95001, Novex, USA) and 
HisPur™ Ni-NTA Resin (Cat # 88221, Thermo Fisher Scentific, USA). Relevant 
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fractions containing the RSV F variants were pooled, concentrated, and subjected to 
size-exclusion chromatography. Fractions corresponding to the trimer peak were 
concentrated, and frozen at −80°C. 
 
3.4 RSV Pre-F- and Post-F-Abs separation by serum adsorption assay:  
Each serum sample (300 ul) was diluted 1:9.7 in 1×  phosphate-buffered saline (PBS) 
and split into three parts. 20 ul of Pre-F or Post-F proteins (0.5 mg/ml) were added to 
970 ul of diluted samples, whereas the positive control, 970 ul of diluted  unadsorbed 
serum, were further diluted 1:10 with 1X PBS. All samples were then incubated  at RT 
for 2-hours, and positive control samples were stored at 4°C until further use. To F-
treated  samples, 10 ul of reconstituted NWSHPQFEK Strep-tag II mAb at 0.5mg/ml 
(Cat # A01732-100, GenScript Biotech, USA) were added, and the  mixture was placed 
on a 360° rotator at 4°C for 2 hours. 80 ul of sheep anti- mouse immunoglobulin G 
Dynabeads (2mg/ml) (Cat # 11206D, Invitrogen, USA) were washed twice  with wash 
buffer [1% bovine serum albumin (BSA), 2M EDTA in 1X PBS (pH 7.4)]. The 
wash  buffer was separated from the beads using a DynaMag-2 magnet (Cat # 12321D, 
Invitrogen, USA). The  Sera-RSV-F-strep-tag II mAb mixture was added to 
corresponding labeled tubes containing  Dynabeads and incubated for 1-hour at RT on a 
rotator. The beads were separated from  supernatant using DynaMag-2; the supernatant 
was stored at 4°C (Ngwuta et al., 2015). Unadsorbed and adsorbed sera were then  used 
in ELISA, and neutralization assay.  
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3.5 RSV Abs detection by enzyme-linked immunosorbent assay (ELISA):  
Plates (96-well) were coated with 100 ul of stabilized Pre-F (1 mg/ml) or Post-F (1 
mg/ml) diluted in 1X PBS (pH 7.4) and incubated overnight at 4°C. Plates were washed 
with wash buffer (0.2% Tween 20 in 1X PBS) and blocked with 200 ul of 5% milk (in 
1X PBS) per well for 1-hour at RT. 100 ul of unadsorbed serum, serum adsorbed with 
Pre-F, and serum adsorbed with Post-F were added to Pre-F– and Post-F–coated wells 
in serial dilutions (1:100 to 1:72900), incubated for 1-hour at RT, washed, and coated 
with 100 ul of goat anti-human IgG-HRP (1:500, Cat # AHI0404, Invitrogen, USA). 
After 1-hour of incubation, the plates were washed, and 100 ul of TMB KPL 
SureBlueTM substrate (Cat # 95059-282, SeraCare, USA) were added to each well, then 
incubated for 20-30 mins. The reaction was stopped by 100 ul of 2M H2SO4 per well. 
An ELISA plate reader (Epoch 2, Biotek, USA) was used to read signals at 450-nm 
wavelength. Using GraphPad Prism, endpoint titers (EP) were calculated from non-
linear curve fitting of data from individual patients, corresponding to the OD reading at 
highest dilution four times above the background. Results are expressed as the inverse 
of logarithm to base 10 (log10) (Hackett, Zhang, Stefanescu, & Pass, 2010).   
 
3.6 Molecular analysis:  
3.6.1 RNA extraction: 
Extraction of viral RNA from 400 ul nasal aspirate samples was performed using a 
QIAamp Viral RNA Extraction miniKit (Catalog # 51106, QIAGEN, Germany) 
according to the manufacturer’s instructions. Extracted RNA were quantified using 
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NanoQuant microplate reader (Infinite Pro M200, Tecan, Switzerland) and stored -
80 oC until used for quantitative and nested RT-PCR. 
3.6.2 Viral quantification by qRT-PCR: 
To measure RSV load in infected infants, extracted RNA was detected using OneStep 
reverse transcriptase quantitative real time PCR kit (Luna® Universal One-Step RT-
qPCR Kit, NEB, US) as per the manufacturer’s recommendations. The primers included 
in the PCR amplification reaction were as following: RSV-AB-1 (5’- 
GGCAAATATGGAAACATACGTGAA-3’), RSV-AB-2 (5’- 
TCTTTTTCTAGGACATTGTAYTGAACAG-3’) and RSV probe (FAM- 
CTGTGTATGTGGAGCCTTCGTGAAGCT- BHQ-1) (Aamir et al., 2013). The 
standard curve was created using extracted RNA from the generated RSV stock (109 
PFU/ml) in serial dilutions to quantify viral RNA load in all the tested samples 
(copies/reaction equivalent to PFU/ml) 
The qRT-PCR reaction was carried out in QuantStudio™ 6 Flex Real-Time PCR 
instrument (Applied Biosystems, USA) using the following cycling conditions: reverse 
transcription at 50°C for 30 min; heat activation at 95°C for 15 min; 40 cycles of 
denaturation at 94°C for 30 s, annealing at 52°C for 30 s, and extension at 72°C for 2 
min; and a final extension step of 72°C for 10 min. 
3.6.3 RSV subtyping by nested RT-PCR: 
RSV subgroups were detected from extracted RNA using a OneStep RT-PCR kit 
(Catalog # 210210, QIAGEN, Germany). The first amplification cycle detecting G gene 
of both subgroups utilized RSV-AB-F (5’-GTCTTACAGCCGTGATTAGG-3’) and 
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RSV-AB-R (5’- GGGCTTTCTTTGGTTACTTC-3’) primers as described (Abels, 
Nadal, Stroehle, & Bossart, 2001). To distinguish between both subgroups, the products 
of the first PCR cycle were used in the second cycle by using RSV-A-F (5’-
GATGTTACGGTGGGGAGTCT-3’), RSV-A-R (5’-GTACACTGTAGTTAATCACA-
3’) primers for group A viruses and RSV-B-F (5’ AATGCTAAGATGGGGAGTT-3’), 
RSV-B-R (5’-GAAATTGAGTTAATGACAG-3’) primers for group B viruses. PCR 
reactions were prepared in a final volume of 50 µl using: 0.25 µl of HotStarTaq DNA 
Polymerase (Catalog # 203203, QIAGEN, Germany), 10 µl of 5X Q-Solution, 5 µl of 
10X PCR buffer which already contains 15mM MgCl2 (all from QIAGEN kit), 1 µl of 
10mM dNTP's (Catalog # N0447S, New England Biolabs, USA), in addition to 1 µl of 
10µM/µl of the primers mentioned above. Both nested RT-PCR reactions were carried 
out in Biometra TAdvanced Twin 48G thermocycler (Analytik Jena, Germany) using 
the following cycling conditions: reverse transcription at 50°C for 30 min; Taq 
polymerase activation at 95°C for 15 min; 40 cycles of denaturation at 94°C for 30 s, 
annealing at 50°C for 60 s, and extension at 72°C for 2 min; and a final extension step 
of 72°C for 10 min. PCR products (first cycle product: 836bp for RSV A and B; and 
second cycle products: 334bp for RSV A and 183bp for RSV B) were detected by gel 
electrophoresis using 1.5% agarose and with ethidium bromide staining [Table 1]. 
3.6.4 F gene sequencing: 
F gene was amplified from all enrolled RSV-infected nasal aspirates (n=65) by nested 
RT-PCR according to the cycling conditions described in this article (Tapia et al., 2014) 
using forward and reverse primers targeting RSV-A and B F1 subunit of F gene [Table 
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1]. Amplified cDNA product was visualized by gel electrophoresis where RSV-A F1 
subunit is 1047bp and RSV-B F1 subunit is 1065bp. Furthermore, the amplified product 
was cleaned-up following PCR purification kit’s procedure (Catalog # 28104, Qiagen, 
USA). Samples were sent to Molecular Cloning Lab (MCLAB) for DNA sanger 
sequencing services. Sequenced data analysis was performed using FinchTV software 
version 1.5 for chromatography reading and using MEGA version 7.0 for sequence 
translation and alignment. Visualization of 3D structure of Pre-F protein was performed 
using Pymol Molecular Graphics System to localize antigenic sites of interest, amino 
acid residues and detected mutations.  
 
 
3.7 Statistical analysis:  
Comparisons between unadsorbed and adsorbed serum samples were done using Two-
way ANOVA and multiple t-tests (paired and unpaired). Correlations between 
continuous variables or/and discrete variables were assessed using Pearson’s correlation 
(in case of parametric data), and Spearman’ (in case of non-parametric data) tests. To 
test for the data’s normality, D'Agostino & Pearson normality test was performed. All 
P-values were compared to a two-sided level of 0.05. All statistical analyses were done 
with GraphPad Prism v7. 
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IV- RESULTS 
 
4.1 Sample collection 
Sixty-five patients diagnosed with RSV-bronchiolitis at PHC-HMC were enrolled in 
this study from February 2017 to February 2018. Blood samples along with nasal 
aspirates were collected from all infected infants following admission and before any 
intervention or treatment. Additionally, blood samples were collected from recruited 
patients’ mothers for comparative analysis. As expected, RSV infections followed a 
seasonality-based trend, where the virus barely circulated during hot months (May 2017 
to September 2017), then dramatically increased in activity during cold months 
(October 2017 to January 2018) [Figure 5].  
 
4.2 Demographic characteristics of enrolled patients 
The main objective of this study is to determine binding and neutralizing antibody titers 
in children diagnosed with primary RSV infection. Accordingly, all RSV-infected 
children in this study were below the age of six months, of which, 89.2% were below 
three months old [Figure 6a].  55.3% of patients were male, with female to male ratio of 
1:1.24 [Figure 6b]. Most observed nationalities were Qatari, Pakistani, then Yemeni 
representing 30.7%, 20%, and 12.3% of total patients’ number, respectively [Figure 
6c]. At the time of admission, clinicians at PEC examined RSV-bronchiolitis severity 
among infected children and gave it a score according to the disease manifestation. Few 
patients were not rated at the time of submission and/or at the time of discharge, 
resulting in total of 62 and 51 rated patients, respectively. Most patients had a score 
between 4 and 6 (77.4%) at admission, and a score of 3 (88.2%) at discharge [Table 2]. 
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4.3 RSV Abs’ binding activities towards Pre-F and Post-F proteins 
The levels of RSV Ab titers in infants and their corresponding mothers were tested by 
ELISA to both conformational structures of F glycoprotein. Sera samples were adsorbed 
with Pre-F and Post-F proteins prior to ELISA testing in order to quantify Pre-F- and 
Post-F-specific Abs. Binding of maternal unadsorbed sera in serial dilutions to both 
proteins revealed equivalent Ab end-point titers to Pre-F and Post-F with an average of 
7.33x103 and 7.75x103, respectively. In infants, serially diluted unadsorbed sera showed 
binding to Pre-F and Post-F proteins with an average of 0.97x103 and 1.12x103 end-
point titer, respectively. These results confirmed the transfer of maternal RSV Abs to 
young infants, yet they represented approximately only 14% of total the maternal RSV 
Pre-F- and Post-F-Abs. In infants, Pre-F adsorbed sera lost 82% of binding capacity to 
Pre-F, and 77% of binding capacity  to Post-F (p<0.05). Similarly, adsorption with Pre-F 
in mothers removed 87% binding capacities to Pre-F and to Post-F (p<0.05). On the 
other hand, adsorption of infant sera with Post-F removed 49% and 74% of the binding 
capacity to Pre-F and Post-F, respectively (p<0.05). Likewise, Post-F adsorption of 
mothers’ sera removed 46% and 78% of binding to Pre-F and Post-F, respectively 
(p<0.05) [Figure 7].  These numbers indicate that approximately 80% of total RSV Abs 
are directed to Pre-F protein in both mothers and corresponding infant. It is worth 
reminding that both F- forms share four antigenic sites, such as site II and site IV, while 
some other antigenic sites like site Ø and site V are strictly found on Pre-F structure and 
are responsible for eliciting high potent Abs (Graham, 2017). 
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4.4 RSV viral load and subgroups circulating among young infected infants 
Quantification of RSV viral load in infected children was done using qRT-PCR on the 
RNA extracted from nasal aspirates. Although all recruited patients in this study were 
initially screened for RSV infection at PEC-HMC using PCR, yet, viral RNA load was 
reperformed to confirm RNA detection and to quantify RSV in all patients. The viral 
load for RSV-positive infants (100%) ranged from 1.73 x 102 to 2.23 x 108, with a mean 
of 4.48 x 107 copies/reaction. 
In parallel, PCR-typing revealed dominance of RSV-A (34%) over RSV-B (19%) 
throughout the study period. Interestingly, 47% of enrolled infants had mixed infections 
(both RSV-A and RSV-B) [Figure 8]. 
 
4.5 Correlation of F antibody titers with demographics and circulating RSV 
subgroups 
The correlation between infants’ anti-F Abs titers with maternal RSV Abs titers, 
patients’ demographic characteristics, RSV load and subgroups were all investigated to 
understand the infection manifestation among young infants. The inspected correlations 
were analyzed by Pearson’s and Spearman’s correlation tests in case of parametric and 
non-parametric samples, respectively. All investigated correlations between 
unadsorbed, Pre-F and Post-F adsorbed sera were evaluated by two-way ANOVA and 
multiple t-tests. Significance was considered at p < 0.05 in all performed statistical 
analysis.  
4.5.1 Association between infants’ and maternal Ab titers 
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We first ran the analysis to study the correlation between infants’ and mothers’ Abs 
titers as indicated above. Our results indicated positive correlation between the 
aforementioned variables (Pearson r= 0.48; p<0.05), demonstrating that the higher RSV 
antibody titers a mother had, the higher they were in her infant and vice-versa [Figure 
9].  
4.5.2 Association of RSV Ab titers (Pre-F and Post-F) with age  
Maternal Abs are known to wean out within 6 months after birth and hence, we aimed at 
analyzing the association between infants’ Pre-F (0.03 x 103 2.81 x 103) and Post-F 
ranged (0.01 x 103 to 3.99 x 103), and age in weeks. Unlike Post-F Abs, Pre-F Abs were 
negatively associated with infants’ age (Pearson r= -0.45; p<0.05). These outcomes 
showed that maternal Pre-F Abs in infants were lower in older infants, concluding that 
Pre-F Abs decrease in titer over time as expected [Figure 10]. 
4.5.3 Association of RSV Ab titers (Pre-F and Post-F) with gender 
Males are known to be more prone to RSV infection than females (Watkiss, 2012). To 
study the correlation of F-specific maternal Abs and gender, Man-Whitney test was 
used. We found no significant correlation between gender and maternal Abs to F-
proteins, suggesting that the levels of RSV Abs do not significantly vary depending on 
gender [figure 11]. 
4.5.4 Association of RSV Ab titers (Pre-F and Post-F) with bronchiolitis score 
Some Ab responses have been shown to elicit enhanced disease illness, like the ones 
seen in FI-RSV vaccine trails. Some of these Abs have been shown to be directed to the 
Post-F form of the protein that is expressed on the FI-virus. Accordingly, we ran an 
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analysis to study the correlation between F-specific antibody titer (Pre- and Post-F) and 
bronchiolitis score which is an indication of infection severity. Surprisingly, no 
significant relationships were established in regards of bronchiolitis score with Pre-F, 
nor with Post-F antibody binding titers (rs = 0.07 and 0.1, respectively; p>0.05) [Figure 
12]. 
4.5.5 Association of RSV Ab titers (Pre-F and Post-F) with viral load and genotypes 
Infection severity and illness are known to increase with the increase of virus replication 
in a particular organ. Accordingly, we estimated viral titers in infected patient and ran 
correlation analysis with sera level of F-specific Abs. Results revealed slightly 
significant inverse correlation between RSV Pre-F antibody binding titers and the viral 
load (Pearson r = -0.28, p<0.05), indicating that as Pre-F Abs decrease, RSV replicates 
more [Figure 13]. Further, we found no correlation between RSV subgroups and Ab 
titers [Figure 14]. 
 
4.6 RSV F gene sequencing analysis 
All enrolled RSV-infected children were included in F gene sequencing method to 
determine potential mutations in most important antigenic sites of F protein. For that, F1 
subunit was selected for sequencing as it includes the most imported Pre-F specific site 
and the most common shared site, site Ø (partially) and site II, respectively. Sequenced 
F1 subunits were translated, aligned and compared to Protein Data Bank # PDB: 4JHW 
as a reference protein. At site Ø (aa196 – 210), amino acids alignment showed a very 
conserved antigenic site among most infants (93.7%), expect in 4 (6.5%) who showed a 
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bulk of amino acid substitutions at positions: 196, 197, 198, 199, 202, 203, 204, 209. 
Meanwhile, at site II (aa255 – 276), amino acids alignment showed variations at 
different positions with different frequencies among infants, of which positions: 258, 
262, 263, 268 and 275 were 100%, 4.7%, 46.8%, 100% and 6.2% substituted, 
respectively [Table 3] [Figure 15]. 
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Table1: RSV detection and subtyping primers used in this study 
 
 
No. Primer Name Sequence (5'–3') Reference 
   I qReal-time RT-PCR for RSV 
1 RSV Forward GGCAAATATGGAAACATACGTGAA 
(Aamir et al., 
2013) 
2 RSV Reverse TCTTTTTCTAGGACATTGTAYTGAACAG 
3 RSV probe 
FAM-CTGTGTATGTGGAGCCTTCGTGAAGCT-
BHQ-1 
II Nested RT-PCR for RSV subtyping 
1 
RSV-AB 
forward 
GTCTTACAGCCGTGATTAGG 
(Abels et al., 
2001). 
2 
RSV-AB 
Reverse 
GGGCTTTCTTTGGTTACTTC 
3 
RSV-A 
Forward 
GATGTTACGGTGGGGAGTCT 
4 
RSV-A 
Reverse 
GTACACTGTAGTTAATCACA 
5 
RSV-B 
Forward 
AATGCTAAGATGGGGAGTTC 
6 
RSV-B 
Reverse 
GAAATTGAGTTAATGACAGC 
III F gene sequencing  
1 
RSV-A F 
forward 
GGC AAA TAA CAA TGG AGT TG 
(Tapia et al., 
2014) 
2 
RSV-A F 
reverse 
AAG AAA GAT ACT GAT CCT G 
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Table 2: Bronchiolitis score given to enrolled infected patients at admission (n=62) 
and at discharge (n=51) 
 
 
Bronchiolitis score at admission No. of patients Percentage (%) 
mild 
3 2 3.225806452 
4 19 30.64516129 
moderate 
5 14 22.58064516 
6 15 24.19354839 
7 5 8.064516129 
severe 
8 6 9.677419355 
11 1 1.612903226 
Bronchiolitis score at discharge No. of patients Percentage (%) 
1 1 1.960784314 
2 5 9.803921569 
3 45 88.23529412 
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Table 3: F1 subunit of fusion protein sequencing results among enrolled RSV-
infected infants for site and site II 
 
 
Antigenic 
site 
Amino 
acid 
position 
Mutations 
Name (%) Reported 
or not 
Effect/importance 
Site ∅ 
(partial) 
196-210 L196D (6.5%) - - 
N197T (6.5%) - - 
Y198A (6.5%) - - 
I199M (6.5%) - - 
G202L (6.5%) - - 
L204P (6.5%) - - 
Site II  255-276 L258N*/C/T 
(*95%) 
- - 
N262C*/K (*3%) reported Resistance to Palivizumab 
neutralization in vivo and 
vitro 
 
 
 
Syncytium formation 
impairment 
D263K*/N (*44%) - 
N268L*/F (*98%) reported 
S275L*/I/M (*3%) reported 
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Figure 5: Monthly distribution of enrolled RSV-infected patients in this study 
from February 2017 to February 2018.  
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Figure 6: Demographic characteristics of all enrolled patients in regards with (a) 
age, (b) gender and (c) nationality. 
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Figure 7: Evaluation of RSV antibody binding activities to both F glycoprotein 
structures in infants and their corresponding mothers by ELISA. Serially diluted 
unabsorbed, Pre-F adsorbed, and Post-F adsorbed sera were tested for binding to Pre-F 
and Post-F proteins and endpoint titers (inverse of log10) were calculated from non-
linear curve fitting. EP titers were plotted in dot plot format and statistical analysis was 
done using Two-way ANOVA tests. Significance was applied when p < 0.05. 
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Figure 8: (a) Detected RSV genotypes among infected infants and (b) their monthly 
distribution throughout the study timeline (from February 2017 to February 2018). 
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Figure 9: Association between infants’ and mothers’ Ab titers to Pre-F-protein. 
Correlation was tested using Pearson’s correlation test r. Significance was applied at p < 
0.05. 
 
 
 
 
 
 
 
Pearson r = 0.48  
p= 0.0019 
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Figure 10: Association between infants’ F-specific Ab titers and age expressed in 
weeks. Analysis was done for both Pre-F (blue) and Post-F (red) Ab titers. This 
correlation was tested using Pearson’s correlation test r. Significance was applied at p < 
0.05.  
Pearson r = -0.45 
*p= 0.0034 
 
Pearson r = -0.09 
p>0.05 
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Figure 11: Association between infants’ Pre-F specific Ab titer and gender. This 
correlation was tested using Man-Whitney test. Significance was applied at p < 0.05. 
 
 
 
 
 
 
 
Figure 12: Association between infants’ Pre-F specific Ab titer and bronchiolitis 
score. This correlation was tested using Spearman’s correlation test rs. Significance was 
applied at p < 0.05. 
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Figure 13: Association between infants’ Pre-F specific Ab binding titer and RSV 
load. This correlation was tested using Pearson’s correlation test r. Significance was 
applied at p < 0.05. 
 
 
 
 
 
 
Figure 14: Association between infants’ F-specific Ab titers and RSV subgroups. 
Correlation matrix and Two-way ANOVA were used. Significance was applied at p < 
0.05. 
Pearson r = -0.28 
*p = 0.04 
 
Pearson r = -0.04 
p>0.05 
 
 
p>0.05 
 
50 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Amino acid alignment of site Ø and site II of F1 subunit of fusion protein 
among enrolled RSV-infected infants 
  
Site Ø Site II 
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V- DISCUSSION 
 
RSV expresses two surface glycoproteins, of which, F protein is metastable and 
changes conformation to a more stable structure spontaneously (Gilman et al., 2016). In 
fact, recent studies showed that an RSV virion loses its Pre-F confirmation structure 
within few hours. Furthermore, formalin inactivation of RSV results in significant 
changes in the F-structure within 72 hours of treatment, which partially explains the 
weakness in immunogenicity and the lack of protection following FI-RSV vaccine trials 
(Killikelly et al., 2016).   Following Pre-F stabilization with cavity-filling-mutations, 
new epitopes were identified on Pre-F which seem to induce more potent Abs than Post-
F. These Pre-F specific epitopes include site Ø, site V and site VIII (Mousa et al., 2017). 
Consequently, stabilized Pre-F has been selected as a potential vaccine candidate. 
Considering failures of previous RSV clinical trials in children, where most vaccines 
induced enhanced disease illness rather than protection, alternative vaccine strategies 
have been considered (Graham et al., 2015). Knowing that infants below 3 months of 
age are the most vulnerable group to RSV infection, it is thought that RSV vaccination 
during pregnancy could boost pre-existing neutralizing antibody titers, providing 
passive protection to newborns (McLellan, Chen, Leung, et al., 2013) (Graham, 2017). 
Previous studies on maternal Abs role in RSV protection were focused on Post-F 
Abs, which were found to be non-protective regardless of their titer levels (Swanson et 
al., 2011). With the availability of Pre-F protein that was generously provided to us by 
our NIH colleagues, we sought for determining the role of maternally derived Pre-F Abs 
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in RSV protection in infants.   Accordingly, magnitude of maternally derived Pre-F Abs 
were determined in 65 RSV-hospitalized infants using binding and neutralizing 
procedures. 
Expectedly, our recruited patients were all below the age of six months in which, 
89.2% of them were below three months old. Gender-wise, 55.3% of them were male. 
And nationality-wise, a huge variability was observed among our samples as Qatar in a 
multi-national county. That said, Qataris, Pakistanis then Yemenis represented 30.7%, 
20%, and 12.3% of patients’ cohort, respectively. To better understand the role of anti-F 
Abs in protection or enhanced diseases illness in hospitalized patients, we recorded data 
about disease manifestation, such as severity and bronchiolitis scores, to include in the 
analysis. Most infants had a score between 4 and 6 (77.4%) at admission, and a score of 
3 (88.2%) at discharge. 
Evaluation of binding activities of maternally transferred RSV Abs revealed low 
presence of Ab levels against Pre-F- and Post-F-directed Abs with an average 0.97x103 
and 1.12x103 end-point titer, respectively. These binding titers are considered 
remarkably low to provide enough neutralizing titers according to previous studies 
which found that a minimum end-point titer of 1:256 (8 log2) is required to provide 
protection from  RSV infection (Piedra, Jewell, Cron, Atmar, & Glezen, 2003) (Jounai 
et al., 2017).  To further investigate the levels of Abs directed to each form of the F-
protein, we ran adsorption assay followed by ELISA binding with both, Pre-F and Post-
F proteins. Unlike Post-F, adsorption of sera samples with Pre-F removed most binding 
activity to both fusion conformations (approximately 80%) in both infants and mothers. 
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These results are similar to what have been reported recently by Ngwuta et al., where 
anti-F Abs accounted for more than 90% of the binding Abs in apparently healthy 
individuals aged between 7 and 93 years old  (Ngwuta et al., 2015). Accordingly, a Pre-
F based vaccine would be ideal to stimulate and boost pre-existing memory B cell 
repertoire in pregnant women to induce high levels of potent maternal Abs. However, 
our study is missing healthy control group, age-matched RSV-negative children, to 
compare RSV antibody levels between affected and non-affected populations to drive 
better conclusions. In fact, it would be more ideal to run a longitudinal study that follow 
up the levels of Abs of infants from birth until six months and relate that to RSV 
infection and mode of illness. Nonetheless, these studies are not easy to do, considering 
all required ethical approvals and commitment of participants.  
Abs could be beneficial or harmful according to their type and epitopes they 
target. Antibody-mediated enhanced disease illness has been reported with many viral 
infections including RSV. In fact, enhanced disease illness in FI-RSV vaccine trials was 
partially attributed to the presence of post-F antibody response (Acosta, Caballero, & 
Polack, 2016). Accordingly, we ran several correlation analyses to study the link 
between Abs level to both F forms, demographics and clinical manifestations. 
Specifically, correlations of maternally transferred RSV Pre-F binding Abs with their 
age, gender, bronchiolitis score, maternal RSV Pre-F antibody titer, and RSV load and 
subgroups were examined. In average, around 14% of maternal pre-F Abs were 
transferred according to our analysis. We found significant correlation of Pre-F Abs in 
infants with mothers’ Pre-F Abs, age (in weeks), and viral load, but not with gender nor 
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with bronchiolitis score. In healthy conditions, neonatal Abs correlate significantly with 
maternal Abs. That is, the higher antibody titer a mother has, the higher level of Abs are 
transferred to her infant (Palmeira, Quinello, Silveira-Lessa, Zago, & Carneiro-
Sampaio, 2011). Consequently, maternally transferred Abs would decrease over time 
and naturally induced Abs would increase following infection. Therefore, it would be 
interesting to follow up with these patients to see whether they elicited Pre-F specific 
response after their primary infection, and whether such response has been affected 
negatively or positively by the levels of maternal Abs. On the other hand, the low levels 
of infant’s Pre-F specific Abs (average 0.97 x 103) are attributed to the low level of 
corresponding mothers [average end-point titers of Pre-F- and Post-F-binding antibody 
were 7.33x103 and 7.75x103, respectively]. Finding 14% of maternally transferred Abs, 
and knowing that a titer of 1:256 (8 log2) is needed for protection, an effective vaccine 
should elicit a minimum titer of 50 log2 in pregnant women to ensure good transfer of 
protective antibody titer in infants. Pre-fusion RSV has been shown to strongly boost 
Pre-F specific neutralizing responses in animal models, reaching 14-fold increase in 
pre-existing titers would result in 4-5-months of neutralizing antibody titers above the 
protective titer of 1:180 in babies (Steff et al., 2017). A clinical trial to test dose, safety, 
tolerability and immunogenicity of a stabilized RSV Pre-F subunit protein vaccine in 
healthy adults is on-going (ClinicalTrials.gov identifier NCT number: NCT03049488). 
Combined results from this trial and our study will provide better insight on the 
potential success rate of the vaccine in pregnant women.  
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No correlation was found between Pre-F antibody levels with gender and 
bronchiolitis score, similarly to few recent studies (Jans et al., 2017). Unlike with 
gender, bronchiolitis score was expected to reflect disease severity and correlate 
negatively with RSV Pre-F Abs or/and positively with Post-F Abs. However, no 
association was observed with Pre-F Abs, nor with Post-F Abs. This could be partially 
attributed to the low level of Pre-F Abs in all enrolled cohorts and to the absence of 
healthy control groups. Further, different clinicians would rate the disease severity in 
patients differently. Finally, a higher number of samples might be needed to generate 
better statistical values for our analysis. 
Molecular analysis revealed high virus titers in the nasal aspirates, with an average of 
4.48 x 107 copies/reaction (PFU/ml) in all recruited infants. This high level of virus 
replication was expected considering the low antibody titer to the F-forms. Since virus 
replication is an indication of illness severity, correlations between Pre-F Abs titers and 
viral titers were tested. We expected a negative relationship between RSV antibody 
titers, mainly Pre-F-directed, and the viral load. Indeed, inverse correlation was seen 
between Pre-F Abs and viral load (p < 0.05). Subgrouping revealed more circulation of 
RSV-A than RSV-B with incidence of 84% vs. 66%, respectively, in which 47% of 
patients had mixed infections. It has been reported that RSV subgroups can coinfect 
individuals either at the same period of throughout a lifetime (Tan et al., 2013). 
However, our mixed infections scores were surprisingly high compared to adjacent 
regions and worldwide. For instance, in Saudi study done in 2014, 77% of RSV-positive 
infants belonged to hRSV-A, and 23% belonged to hRSV-B.  And a co-infection with 
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both strains represented 5.7% (Ahmed et al., 2016). While in Morocco, it was 
documented that among 18.2% of RSV-positive cases, a mixed infection of RSV-A and 
RSV-B was witnessed in 37.9% (Jroundi et al., 2016). Meanwhile in China, a 3-year 
study revealed that 51.2% of patients were RSV-A positive compared to 48.8% RSV-B 
positive. No co-infection with both viruses was reported (W. Liu et al., 2016). Both 
RSV subgroups can be recognized through cross-reactive antibodies indicating presence 
of cross-immunity to both subgroups, then through the high variable region of G gene 
(Tan et al., 2013). Unless our co-infected children go to a common nursery, or acquired 
the second viral infection from the PEC itself, our findings require further analysis and 
confirmation to determine an accurate RSV subgrouping prevalence. 
No correlation was found between antibody titers to Pre-F/Post-F and RSV 
subgroups A and B, where subgrouping is determined based on G-protein rather than F- 
protein. Interestingly, we could not detect amplified fragment by gel electrophoresis 
following by nested RT-PCR in one out of 65 patients, although all samples tested 
positive at PEC – HMC and at BRC - QU using PCR and displayed RSV-like illness. 
These discrepancies might be due to low RNA quality and quantity, or due to presence 
of G gene mutations in this patient. 
F gene sequencing was performed among all enrolled RSV-infected children to 
investigate the presence of any potential mutations in the most imported Pre-F specific 
antigenic site and the most common shared site targeted by the only approved 
prophylactic drug, site Ø (partially) and site II, respectively. Amino acids alignment in 
site Ø (aa196-210) conserved among 93.7% of isolated RSV. Yet, 6.5% of them had the 
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following mutations: L196D, N197T, Y198A, I199M, G202L, L203A, L204P, L209T. 
These exact mutations were interestingly never reported before it the literature. Instead, 
D200N, K201N, and K209Q were the most reported ones at site Ø in other studies 
(Okamoto et al., 2018) (Hause et al., 2017). To eliminate any bias outcomes, 
reperforming F gene sequencing is highly considered to validate our mutations. Further, 
once confirmed, and if those mutations happen to at the binding site of monoclonal site 
Ø Pre-F specific antibodies, this could affect the virus neutralization by maternal 
antibodies and thus explain infants’ hospitalization with RSV. Regarding site II (aa255 
– 276), amino acids alignment showed variations of mutation frequencies among 
infants, such as: L258N, N262C, D263K, N268L and S275L. Compared to literature, 
N262K, N268I/L and S275L mutations were reported in other studies (Chen et al., 
2018) (Hashimoto & Hosoya, 2017; Ogunsemowo, Olaleye, & Odaibo, 2018) and 
showed resistance of mutant RSV isolates to Palivizumab neutralization, knowing that 
its binding site is aa262 to aa276 (Hause et al., 2017). It would be interesting to follow 
up with our patients to investigate whether isolated mutant viruses acquired resistance 
to Palivizumab or/and to Pre-F Abs. These findings could be in favor of introducing 
stabilized Pre-F antigen as a vaccine in pregnant woman since circulating RSV started 
acquiring mutations at the binding site of the only prophylactic drug, resulting in 
resistance to its neutralizing activity. 
Further analysis like measuring RSV neutralization should be tested in future. 
Nonetheless, we expect very low titers of neutralizing Abs considering all the above 
findings.  Additionally, it would also be important to run similar analysis on age-
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matched RSV-negative controls to validate most of our conclusions. However, 
recruitment of more patients for the sake of this study was a huge obstacle due to the 
virus seasonality, and hesitation of guardians to enroll their kids in the study.  
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VII-CONCLUSION 
 
This is the first study that aims at providing an evidence-based overview on the 
contribution of Pre-F specific maternal Abs in RSV protection. Data from this study 
shall guide the development of strategies to evaluate Pre-F RSV vaccine in pregnant 
women.  Our results indicated that only 14% of maternal Abs to RSF F-protein are 
transferred to their infants.  Having in mind that at titer of at least 1:256 (8 log2) is 
required for protection in infants below the age of 6 months, a vaccine shall induce an 
antibody titer of 50 log2 in pregnant women to insure sufficient transfer of protective 
Abs. According to other studies,  approximately “every 2-fold rise in cord blood 
neutralizing antibody titers reduces the risk of RSV-associated hospitalization in the 
first 6 months of life by 26–30%” (Steff et al., 2017). This approach seems very 
applicable considering our findings, where Pre-F Abs represented more than 80% of the 
response in infants’ and mothers’ samples. That is, a Pre-F vaccine would stimulate and 
boost pre-existing Pre-F specific memory B cell repertoire in pregnant women to induce 
high levels of potent Abs.     
A major drawback in our study is that we analyzed F-forms RSV Abs only at one 
time point which is not a good indicative of the maternal antibody transfer in this 
regard. Accordingly, an ideal analysis would involve a serial sampling of infants in their 
first six months of life, while RSV monitoring infection status. This kind of study is 
hard to manage due to the needed ethical approvals, commitment of enrolled families, 
and continuous follow-up.  
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Interestingly, we could not find any correlation between Pre-F antibody titers and 
clinical manifestations such as gender, bronchiolitis score. This could be attributed to 
several factors including: low number of samples, inconsistency of reporting severity 
score between different practitioners, and absence of healthy control. Further, our 
analysis was focused on Pre-F Abs considering their protective potential, while a deeper 
analysis on Post-F might be required considering their recognized effect on enhanced 
disease illness.  
Few groups have recently started phase 1 to 3 clinical trials implementing 
different RSV vaccines in adults and elderly people (Falloon et al., 2016). Importantly 
for us, a study is currently running in the USA in collaboration between NIH Vaccine 
Research Center and Novavax company to test RSV Pre-F+Alum in pregnant women in 
their last trimester. The study, which is anticipated to be completed on May 2020, aims 
to determine the safety, immunogenicity, and efficacy of this vaccine in protecting 
young infants from RSV infection after 90 days from delivery through maternal 
immunization (Thomas, 2020). It would be ideal to contribute in making such clinical 
trials successful by providing more conclusive finding in regards to support the 
importance of introducing RSV Pre-F antigen vaccine to pregnant mothers.  
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